Leadless Pacemakers Market: as Abbott’s AVEIR DR becomes the first dual-chamber leadless system to reach commercial scale and Boston Scientific pursues FDA approval for a leadless pacemaker that communicates wirelessly with a subcutaneous defibrillator, the category is completing its transition from a single-chamber niche into the default first-line pacing consideration across the full indication spectrum, so the competitive battle has shifted from proving leadless pacing works at all to which company can extend it to dual-chamber synchrony, conduction system pacing, and defibrillator-integrated therapy first.

The global leadless pacemakers market size was USD 3.48 Billion in 2025 and is expected to register a revenue CAGR of 11.2% during the forecast period. Market revenue growth is driven by factors such as Medtronic’s Micra transcatheter pacing system sustaining mid-20s percentage revenue growth as a primary cardiac rhythm and heart failure growth driver, Abbott’s AVEIR DR dual-chamber leadless pacemaker accelerating adoption as the category’s first commercially available dual-chamber system, and Boston Scientific’s pursuit of FDA approval for a leadless pacemaker designed to communicate wirelessly with a subcutaneous defibrillator. The first driving factor is Medtronic’s continued Micra transcatheter pacing system growth, which the company’s SEC filings identify as a primary driver of its cardiac rhythm and heart failure business segment. Medtronic reported that its Micra transcatheter pacing system sustained mid-20s percentage revenue growth in the third quarter of fiscal year 2025, according to the company’s 10-Q SEC filing, reflecting sustained leadless pacemaker adoption momentum within an established, single-chamber product category. The second driving factor is Abbott’s AVEIR DR dual-chamber leadless pacemaker, the first commercially available leadless system capable of atrioventricular synchronous pacing, extending leadless pacing to a broader range of bradycardia indications than single-chamber devices alone can address. Abbott reported that its cardiac rhythm management business sustained approximately 10% growth in the second quarter of fiscal year 2025, driven by accelerating AVEIR adoption, and presented late-breaking AVEIR conduction system pacing feasibility study data in April 2025 demonstrating the world’s first leadless pacemaker delivering conduction system pacing. The third driving factor is Boston Scientific’s pursuit of FDA approval for its EMPOWER leadless pacemaker and modular cardiac rhythm management (mCRM) system, designed to communicate wirelessly with the company’s EMBLEM subcutaneous implantable defibrillator. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each successive leadless pacemaker capability extension, from single-chamber to dual-chamber to conduction system pacing to defibrillator integration, widens the pool of bradycardia patients eligible for a fully leadless solution, letting the category capture procedure volume that previously required a traditional transvenous pacemaker with leads. Once a leadless pacemaker platform gains dual-chamber synchrony capability, conduction system pacing capability, or defibrillator communication capability, patients who previously required a traditional lead-based pacemaker specifically because their indication needed one of these capabilities become eligible for a fully leadless alternative, so each capability extension directly expands the leadless-eligible patient population rather than simply improving an existing indication. As a result, demand and revenue share are concentrating around the three companies capable of sustaining simultaneous capability-extension R&D investment, Medtronic, Abbott, and Boston Scientific, and the forecast tilts toward leadless pacemakers becoming the default first-line consideration across the full bradycardia indication spectrum rather than a niche alternative reserved for specific patient profiles. For instance, Abbott presented late-breaking AVEIR conduction system pacing feasibility study data in April 2025 demonstrating the world’s first leadless pacemaker delivering conduction system pacing, a capability historically requiring a traditional lead-based system, directly extending leadless pacing eligibility to a patient population that previously had no fully leadless option. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the sustained growth trajectory of Medtronic’s Micra transcatheter pacing system, the category’s original and most established leadless pacemaker platform. A company’s own SEC filing identifying a specific product as a primary segment growth driver is a meaningfully stronger signal of sustained demand than general market commentary, since it reflects management’s own assessment reported under securities law disclosure obligations, so Medtronic’s SEC filing language and genuine underlying Micra demand strength are directly linked. Medtronic reported that its Micra transcatheter pacing system sustained mid-20s percentage revenue growth in the third quarter of fiscal year 2025, according to the company’s 10-Q SEC filing, reflecting continued adoption momentum nearly a decade after the platform’s original FDA approval. The effect on the market is that leadless pacemaker adoption has moved well beyond an early-adopter phase into sustained, broad-based clinical practice growth even within the single-chamber category alone. These are some of the key factors driving revenue growth of the market.

The second driver is Abbott’s AVEIR DR dual-chamber leadless pacemaker, which extends fully leadless pacing to atrioventricular synchronous pacing indications for the first time. A meaningful share of bradycardia patients require atrioventricular synchrony that single-chamber leadless devices cannot provide, and AVEIR DR’s dual-chamber capability directly addresses this previously leadless-ineligible patient population, so the device’s technical capability and its addressable market expansion are directly linked rather than simply an incremental product improvement. Abbott reported that its cardiac rhythm management business sustained approximately 10% growth in the second quarter of fiscal year 2025, driven by accelerating AVEIR adoption, and presented late-breaking AVEIR conduction system pacing feasibility study data in April 2025 demonstrating the world’s first leadless pacemaker delivering conduction system pacing. The effect on the market is that Abbott’s dual-chamber and conduction system pacing capability extensions are converting leadless pacing from a single-chamber niche into a viable option across a substantially broader bradycardia indication spectrum. These are some of the key factors driving revenue growth of the market.

“Abbott’s April 2025 late-breaking AVEIR conduction system pacing feasibility study demonstrated the world’s first leadless pacemaker delivering conduction system pacing, a capability that historically required a traditional lead-based pacing system, extending fully leadless pacing eligibility to a patient population that previously had no leadless alternative.”

The third driver is Boston Scientific’s development of a leadless pacemaker designed specifically to integrate with a subcutaneous implantable defibrillator, extending leadless technology beyond standalone pacing into combined cardiac rhythm management therapy. Combining leadless pacing with defibrillator therapy requires wireless device-to-device communication technology that neither a standalone leadless pacemaker nor a standalone defibrillator alone provides, and this integration is precisely what Boston Scientific’s modular cardiac rhythm management system is designed to achieve, so the technical integration challenge and the resulting new therapy category are directly linked. Boston Scientific’s MODULAR ATP pivotal trial met its primary six-month safety and efficacy endpoints, with a 97.5% major complication-free implant rate and 98.8% successful device-to-device communication, and the company has stated it will pursue FDA approval for the EMPOWER leadless pacemaker and modular cardiac rhythm management system in 2025. The effect on the market is that leadless pacemaker technology is positioned to extend beyond standalone bradycardia pacing into combined pacing-and-defibrillation therapy for patients who previously required two separate lead-based systems. These are some of the key factors driving revenue growth of the market.

However, the leadless pacemakers market faces adoption constraints from the higher device cost of leadless systems relative to traditional transvenous pacemakers, procedural and retrieval complexity specific to leadless device implantation and eventual replacement, and physician training and procedural volume requirements for the newest dual-chamber and conduction system pacing techniques. Because leadless pacemakers carry a meaningful device cost premium over traditional transvenous pacemaker and lead systems, reflecting the more sophisticated catheter-based delivery and fixation engineering required, hospital capital budget and payer reimbursement considerations continue to influence adoption pace even as clinical evidence increasingly favours leadless systems on complication rate and infection risk grounds relative to lead-based alternatives. Device retrieval and replacement complexity is a second constraint, since leadless pacemakers require a specialised catheter-based retrieval procedure at end of battery life or device failure rather than the more familiar generator-and-lead replacement process used with traditional pacemakers, and while retrieval techniques have matured considerably since the category’s original commercial launch, this procedural difference still represents a genuine learning curve for physicians and a planning consideration for long-term patient management. Physician training and procedural volume requirements are the third constraint, since achieving proficiency with leadless pacemaker implantation generally, and particularly with the newest dual-chamber synchronous pacing and conduction system pacing techniques specifically, requires dedicated training and sustained procedural volume that not every implanting physician or centre has yet accumulated, meaning the newest capability extensions will take time to diffuse from specialist electrophysiology centres into broader clinical practice. These factors substantially limit leadless pacemakers market growth over the forecast period.

Based on product, the global leadless pacemakers market is segmented into single-chamber and dual-chamber leadless pacemakers. Single-chamber leadless pacemakers hold the largest revenue share, because Medtronic’s Micra platform has established the longest commercial track record and broadest installed base within the category, which suits the product’s sustained mid-20s percentage revenue growth reported in the company’s SEC filings. Dual-chamber leadless pacemakers are expected to register the fastest revenue growth rate in the global leadless pacemakers market over the forecast period, driven directly by Abbott’s AVEIR DR adoption acceleration, which is why this category represents the leading edge of leadless pacemaker technology extension.

Ventricular (VVI) pacing chamber configuration is expected to account for the largest revenue share in the global leadless pacemakers market during the forecast period

Based on chamber, the global leadless pacemakers market is segmented into ventricular (VVI) pacing and atrioventricular (DR) synchronous pacing configurations. Ventricular (VVI) pacing holds the largest revenue share, reflecting the established, broad clinical indication base for single-chamber ventricular pacing that Medtronic’s Micra platform has served since its original commercial launch. Atrioventricular (DR) synchronous pacing is expected to register the fastest revenue growth rate in the global leadless pacemakers market over the forecast period, driven directly by AVEIR DR adoption and Abbott’s April 2025 conduction system pacing feasibility data, which is why this configuration represents the newest and fastest-expanding chamber category.

Based on regional analysis, the leadless pacemakers market in North America accounted for largest revenue share in 2025. The United States leads because Medtronic, Abbott, and Boston Scientific, the three companies driving nearly all leadless pacemaker capability extension globally, concentrate significant commercial, clinical trial, and regulatory activity in the country. Abbott’s April 2025 AVEIR conduction system pacing feasibility data and Boston Scientific’s pursuit of EMPOWER FDA approval both concentrate first within the United States regulatory and clinical trial environment. The concentration of leadless pacemaker capability-extension R&D and FDA regulatory activity in the United States also means new leadless pacing technology is typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national leadless pacemakers markets within Europe. The region’s well-established electrophysiology infrastructure and CE-marking regulatory pathway sustain steady demand, and several leadless pacemaker capability extensions have received European approval on a comparable or earlier timeline to United States FDA approval. The result is steady rather than rapid growth, shaped more by the region’s already-mature electrophysiology procedural infrastructure than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and South Korea represent the three largest national leadless pacemakers markets within the region. Expanding electrophysiology procedural capacity and rising cardiac arrhythmia diagnosis rates in China are driving new leadless pacemaker demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national leadless pacemakers markets within the region. Specialist cardiac centres in both countries are gradually adopting leadless pacing technology, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised leadless pacemaker delivery systems that Latin American cardiac centres depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial leadless pacemakers markets within the GCC. The UAE is the most established leadless pacemakers market on the continent given its concentrated private cardiac centre infrastructure, while the wider Gulf states and broader African markets are still building the specialist electrophysiology capacity that leadless pacemaker implantation depends on.